What is the 13F Pro Quality Score for AQST?

13F Pro ranks Aquestive Therapeutics, Inc. (AQST) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AQST's current score at https://13fpro.ai/research/AQST (free sign-up required for the full ranking).

Which hedge funds own the most AQST stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AQST include Bratton Capital Management, L.P., BlackRock,, RTW INVESTMENTS,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AQST as soon as new 13F filings post.

Where does 13F Pro source AQST data?

All Aquestive Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Aquestive Therapeutics, Inc. files with the SEC under CIK 1398733. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AQST in?

Aquestive Therapeutics, Inc. (AQST) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AQST research updated on 13F Pro?

AQST's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Aquestive Therapeutics, Inc.(AQST)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1398733 AQST stock profile & AI dashboard →

13F Pro Quality Score

11.7/100

Rank #2,790 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

22.1/100

Profitability

6.4/100

Balance Sheet

5.3/100

Earnings Quality

30.0/100

Free Cash Flow

6.1/100

Institutional Flow

14.4/100

Revenue Scale

10.2/100

Dilution Risk

11.0/100

AQST Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Aquestive Therapeutics, Inc. (AQST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AQST at 11.7/100 on a 32-signal composite quality model, placing it at rank #2,790 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (5.3) and free cash flow (6.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Aquestive Therapeutics, Inc. reports quarterly revenue of $14.4M, net income of $-8.1M, free cash flow of $-14.9M. Top institutional holders of AQST by reported 13-F value include Bratton Capital Management, L.P., BlackRock,, RTW INVESTMENTS,, based on the most recent SEC filings. AQST trades on the Nasdaq exchange and files with the SEC under CIK 1398733. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AQST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aquestive Therapeutics, Inc. directly from SEC EDGAR. Aquestive Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 27 since 2021, currently 11.7 — an improving long-term trajectory across 28 quarterly and live scoring snapshots.

✦

Fun facts about Aquestive Therapeutics, Inc.

Quirks, history, and lore behind AQST — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · small-cap · listed on Nasdaq · headquartered in New Jersey.
2
The Numbers
Annual revenue in the range of tens of millions of dollars — this is not a pharma giant, but a focused clinical-stage-adjacent company commercializing a narrow product portfolio.
3
The History
Spun out from MonoSol Rx technology roots, the company built its identity around thin-film drug delivery — the kind of technology that dissolves on or under your tongue.
4
The Secret
Its core platform puts medicines into orally dissolving film strips, bypassing the need to swallow pills — useful for patients who can't, or for drugs that need to act fast.
5
The Lore
One of its lead programs targets epileptic seizures with a fast-acting rescue therapy, competing in a space where speed of delivery can be a matter of life and death.
6
The Giveaway
Ticker AQST, this New Jersey biotech's name is a mash-up of 'quest' and something aqueous — fitting for a company whose drugs dissolve the moment they hit your mouth.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$14.4M

Net Income

Q1 2026

$-8.1M

Free Cash Flow

Q1 2026

$-14.9M

ROIC

Q1 2026

-38.4%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-22.6% YoY

$44.5MFY 2025

FY20 $45.8MFY22 $47.7MFY24 $57.6MFY25 $44.5M

Net Income

-89.8% YoY

$-83.8MFY 2025

FY20 $-55.8MFY22 $-54.4MFY24 $-44.1MFY25 $-83.8M

Operating Income

-130.9% YoY

$-71.1MFY 2025

FY20 $-42.9MFY22 $-42.1MFY24 $-30.8MFY25 $-71.1M

EPS (Diluted)

-52.9% YoY

$-0.78FY 2025

FY20 $-1.66FY22 $-1.12FY24 $-0.51FY25 $-0.78

Total Assets

+58.2% YoY

$160.4MFY 2025

FY20 $62.9MFY22 $57.1MFY24 $101.4MFY25 $160.4M

Total Debt

+0.0% YoY

$45.0MFY 2025

FY20 $51.5MFY22 $33.4MFY24 $45.0MFY25 $45.0M

Op. Cash Flow

-46.6% YoY

$-52.4MFY 2025

FY20 $-45.5MFY22 $-9.8MFY24 $-35.8MFY25 $-52.4M

Metric	FY 2025	FY 2024	FY 2022	FY 2020	FY 2018	FY 2016
Revenue	$44.5M -22.6%	$57.6M +20.7%	$47.7M +4.0%	$45.8M -32.0%	$67.4M	—
Net Income	$-83.8M -89.8%	$-44.1M +18.9%	$-54.4M +2.5%	$-55.8M +9.1%	$-61.4M	—
Operating Income	$-71.1M -130.9%	$-30.8M +26.9%	$-42.1M +1.9%	$-42.9M +12.3%	$-48.9M	—
EPS (Diluted)	$-0.78 -52.9%	$-0.51 +54.5%	$-1.12 +32.5%	$-1.66	—	—
Total Assets	$160.4M +58.2%	$101.4M +77.7%	$57.1M -9.2%	$62.9M -27.6%	$86.9M	—
Total Debt	$45.0M +0.0%	$45.0M +34.5%	$33.4M -35.1%	$51.5M	—	—
Operating Cash Flow	$-52.4M -46.6%	$-35.8M -264.2%	$-9.8M +78.4%	$-45.5M -249.9%	$-13.0M	—

Get alerted when AQST's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Aquestive Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AQST

Bratton Capital Management, L.P.
$40.7M9,810,958 sh
BlackRock, Inc.
$31.2M7,509,071 sh
RTW INVESTMENTS, LP
$30.8M7,426,471 sh
Arete Wealth Advisors, LLC
$14.1M121,485 sh
FEDERATED HERMES, INC.
$12.2M2,940,339 sh
BALYASNY ASSET MANAGEMENT L.P.
$12.0M2,900,570 sh
STATE STREET CORP
$10.6M2,546,191 sh
Samsara BioCapital, LLC
$10.4M2,500,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$10.0M2,408,191 sh
BANK OF AMERICA CORP /DE/
$10.0M2,405,050 sh

Fund	Value	Shares
Bratton Capital Management, L.P.	$40.7M	9,810,958
BlackRock, Inc.	$31.2M	7,509,071
RTW INVESTMENTS, LP	$30.8M	7,426,471
Arete Wealth Advisors, LLC	$14.1M	121,485
FEDERATED HERMES, INC.	$12.2M	2,940,339
BALYASNY ASSET MANAGEMENT L.P.	$12.0M	2,900,570
STATE STREET CORP	$10.6M	2,546,191
Samsara BioCapital, LLC	$10.4M	2,500,000
GEODE CAPITAL MANAGEMENT, LLC	$10.0M	2,408,191
BANK OF AMERICA CORP /DE/	$10.0M	2,405,050

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AQST on your watchlist

Track score changes the day Aquestive Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AQST a good stock to buy?

13F Pro's AI-powered analysis of Aquestive Therapeutics, Inc. (AQST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AQST are available on the AQST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AQST?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AQST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aquestive Therapeutics, Inc.'s investment landscape.